Last updated on September 2018

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

Brief description of study

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Clinical Study Identifier: NCT02576574

Contact Investigators or Research Sites near you

Start Over

Igor Lifirenko

RBIH "Kursk regional clinical oncology dispensary" of Kursk Region Healthcare Committee
Kursk, Russian Federation
  Connect »